ACR O-RADS超声对1054个附件肿块的验证研究
该回顾性研究纳入两家医院1054个有病理结果的附件病变,评估ACR O-RADS US的诊断效能与观察者间一致性。O-RADS 5、4、3、2的恶性率分别为89.57%、34.46%、1.10%、0.45%,AUC为0.960,以>O-RADS 3为最佳截断值的敏感度和特异度分别为98.7%和83.2%,不同经验医师间一致性良好(κ=0.714)。将O-RADS 4细分为4a和4b可改善中间风险分层。
要点
- O-RADS US对附件肿块恶性风险分层有效,AUC达0.960。
- 以>O-RADS 3为恶性预测最佳截断值,敏感度98.7%、特异度83.2%。
- O-RADS 4细分为4a和4b后恶性率分别为17.02%和42.57%,分层更优。
核心结论
- ACR O-RADS US对附件病变提供有效的恶性风险分层,且不同经验放射科医师间可靠性高。
- 将O-RADS 4病变细分为4a和4b两组有助于改善中间风险的分层。
研究设计与样本
- 按O-RADS US标准对每个病变分类,采用Kappa统计评估低年资与专家放射科医师间观察者一致性。
主要发现
- 1054个附件病变中750个良性、304个恶性。
- O-RADS 5、4、3、2病变的恶性率分别为89.57%、34.46%、1.10%、0.45%。
- ROC曲线下面积为0.960(95% CI,0.947-0.971)。
- 以>O-RADS 3为恶性预测最佳截断值,敏感度98.7%(95% CI,0.964-0.996),特异度83.2%(95% CI,0.802-0.858)。
- O-RADS 4中多房囊肿与光滑实性病变归为4a、其余含实性成分囊性病变归为4b,恶性率分别为17.02%和42.57%(P < 0.001)。
关键数值与推荐
- O-RADS 5、4、3、2病变的恶性率分别为89.57%、34.46%、1.10%、0.45%。
- 恶性预测最佳截断值为>O-RADS 3,敏感度98.7%(95% CI,0.964-0.996),特异度83.2%(95% CI,0.802-0.858)。
- O-RADS 4a与4b的恶性率分别为17.02%和42.57%(P < 0.001)。
临床怎么用
- 可采用O-RADS US对附件肿块进行恶性风险分层,以>O-RADS 3作为提示恶性的截断值。
- 对O-RADS 4病变可进一步细分为4a和4b,以改善中间风险患者的分层管理。
局限性
- 本研究为回顾性设计,仅纳入有病理结果的病变,可能存在选择偏倚。
- 观察者间一致性仅比较了低年资与专家放射科医师各一名。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess the diagnostic performance and inter-observer agreement of the American College of Radiology (ACR) Ovarian-Adnexal Reporting and Data System Ultrasound (O-RADS US). METHODS: From January 2016 to December 2018 a total of 1054 adnexal lesions in 1035 patients with pathologic results from two hospitals were retrospectively included. Each lesion was assigned to an O-RADS US category according to the criteria. Kappa (κ) statistics were applied to assess inter-observer agreement between a less experienced and an expert radiologist. RESULTS: Of the 1054 adnexal lesions, 750 were benign and 304 were malignant. The malignancy rates of O-RADS 5, O-RADS 4, O-RADS 3, and O-RADS 2 lesions were 89.57%, 34.46%, 1.10%, and 0.45% respectively. Area under the receiver operating characteristic curve was 0.960 (95% CI, 0.947-0.971). The optimal cutoff value for predicting malignancy was >O-RADS 3 with a sensitivity and specificity of 98.7% (95% CI, 0.964-0.996) and 83.2% (95% CI, 0.802-0.858) respectively. When sub-classifying multilocular cysts and smooth solid lesions in O-RADS 4 lesions as O-RADS 4a lesions and the rest cystic lesions with solid components as O-RADS 4b lesions, the malignancy rate were 17.02% and 42.57% respectively, which showed better risk stratification (P < 0.001). The inter-observer agreement between a less-experienced and an expert radiologist of O-RADS categorization was good (κ = 0.714). CONCLUSIONS: The ACR O-RADS US provides effective malignancy risk stratification for adnexal lesions with high reliability for radiologists with different experience. Sub-grouping of O-RADS 4 lesions into two groups facilitated better stratification of the intermediate risk.
引用
- Cao L, Wei M, Liu Y, et al. Validation of American College of Radiology Ovarian-Adnexal Reporting and Data System Ultrasound (O-RADS US): Analysis on 1054 adnexal masses. Gynecol Oncol. 2021. PMID: 33966893. doi:10.1016/j.ygyno.2021.04.031
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。